Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 425

1.

CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.

Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M.

Cell Rep. 2019 Dec 10;29(11):3405-3420.e5. doi: 10.1016/j.celrep.2019.11.008.

PMID:
31825825
2.

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues.

Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF.

BMC Cancer. 2019 Dec 5;19(1):1189. doi: 10.1186/s12885-019-6363-0.

3.

Structural, rheological and dynamic aspects of hydrogen-bonding molecular liquids: Aqueous solutions of hydrotropic tert-butyl alcohol.

Cerar J, Jamnik A, Pethes I, Temleitner L, Pusztai L, Tomšič M.

J Colloid Interface Sci. 2020 Feb 15;560:730-742. doi: 10.1016/j.jcis.2019.10.094. Epub 2019 Oct 25.

PMID:
31704003
4.

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF.

J Clin Oncol. 2019 Oct 28:JCO1900693. doi: 10.1200/JCO.19.00693. [Epub ahead of print]

PMID:
31657982
5.

Identification of a novel MYOC variant in a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure.

Criscione J, Ji W, Jeffries L, McGrath JM, Soloway S, Pusztai L, Lakhani S.

Cold Spring Harb Mol Case Stud. 2019 Dec 13;5(6). pii: a004374. doi: 10.1101/mcs.a004374. Print 2019 Dec.

6.

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.

Wali VB, Patwardhan GA, Pelekanou V, Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L.

Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w.

7.

Molecular Dynamics Simulation Studies of the Temperature-Dependent Structure and Dynamics of Isopropanol-Water Liquid Mixtures at Low Alcohol Content.

Pothoczki S, Pusztai L, Bakó I.

J Phys Chem B. 2019 Sep 5;123(35):7599-7610. doi: 10.1021/acs.jpcb.9b05631. Epub 2019 Aug 26.

PMID:
31405282
8.

Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.

Pusztai L, Foldi J, Dhawan A, DiGiovanna MP, Mamounas EP.

Lancet Oncol. 2019 Jul;20(7):e390-e396. doi: 10.1016/S1470-2045(19)30158-5. Review.

PMID:
31267973
9.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L.

Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.

10.

The impact of communication style on patient satisfaction.

Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L.

Breast Cancer Res Treat. 2019 Jul;176(2):349-356. doi: 10.1007/s10549-019-05232-w. Epub 2019 Apr 25.

PMID:
31025271
11.

Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.

Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R.

Breast Cancer Res Treat. 2019 Jul;176(2):261-270. doi: 10.1007/s10549-019-05178-z. Epub 2019 Apr 24. Review.

PMID:
31020471
12.

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.

Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh ZA, Hayes DF, Hortobagyi GN, Barlow WE, Hatzis C, Pusztai L.

J Immunother Cancer. 2019 Apr 10;7(1):88. doi: 10.1186/s40425-019-0563-7.

13.

Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.

Foldi J, O'Meara T, Marczyk M, Sanft T, Silber A, Pusztai L.

J Clin Oncol. 2019 Jun 1;37(16):1365-1369. doi: 10.1200/JCO.18.01933. Epub 2019 Apr 3. No abstract available.

PMID:
30943126
14.

Immunotherapy and targeted therapy combinations in metastatic breast cancer.

Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L.

Lancet Oncol. 2019 Mar;20(3):e175-e186. doi: 10.1016/S1470-2045(19)30026-9. Review.

PMID:
30842061
15.

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.

O'Meara T, Safonov A, Casadevall D, Qing T, Silber A, Killelea B, Hatzis C, Pusztai L.

Breast Cancer Res Treat. 2019 May;175(1):247-259. doi: 10.1007/s10549-019-05156-5. Epub 2019 Feb 6.

PMID:
30725384
16.

TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.

Gershkovich P, Platt J, Knopf J, Tasoulis MK, Shi W, Pusztai L, Hatzis C.

JCO Clin Cancer Inform. 2018 Dec;2:1-13. doi: 10.1200/CCI.17.00120.

17.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy530. [Epub ahead of print] No abstract available.

18.

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.

Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL.

Breast Cancer Res. 2018 Dec 17;20(1):154. doi: 10.1186/s13058-018-1076-x.

19.

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity.

Shi W, Ng CKY, Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Gerstein MB, Chagpar AB, Weigelt B, Pusztai L, Reis-Filho JS, Hatzis C.

Cell Rep. 2018 Nov 6;25(6):1446-1457. doi: 10.1016/j.celrep.2018.10.046.

20.

Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer.

Kratz J, Burkard M, O'Meara T, Pusztai L, Veitch Z, Bedard PL.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:56-64. doi: 10.1200/EDBK_200731. Review.

21.

Immunological differences between primary and metastatic breast cancer.

Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L.

Ann Oncol. 2018 Nov 1;29(11):2232-2239. doi: 10.1093/annonc/mdy399.

PMID:
30203045
22.

Increased epigenetic age in normal breast tissue from luminal breast cancer patients.

Hofstatter EW, Horvath S, Dalela D, Gupta P, Chagpar AB, Wali VB, Bossuyt V, Storniolo AM, Hatzis C, Patwardhan G, Von Wahlde MK, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L.

Clin Epigenetics. 2018 Aug 29;10(1):112. doi: 10.1186/s13148-018-0534-8.

23.

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK.

Oncologist. 2019 Mar;24(3):313-318. doi: 10.1634/theoncologist.2018-0213. Epub 2018 Aug 23.

PMID:
30139836
24.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

25.

Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.

Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li FY, Zhou Y, Chagpar A, Ferrucci LM, Pusztai L, Irwin ML.

Breast Cancer Res Treat. 2018 Nov;172(1):105-112. doi: 10.1007/s10549-018-4895-7. Epub 2018 Jul 30.

PMID:
30062572
26.

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C.

JAMA Oncol. 2018 Nov 1;4(11):e181564. doi: 10.1001/jamaoncol.2018.1564. Epub 2018 Nov 8.

27.

Variations of the Hydrogen Bonding and Hydrogen-Bonded Network in Ethanol-Water Mixtures on Cooling.

Pothoczki S, Pusztai L, Bakó I.

J Phys Chem B. 2018 Jul 5;122(26):6790-6800. doi: 10.1021/acs.jpcb.8b02493. Epub 2018 Jun 25.

PMID:
29893130
28.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.

29.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805. No abstract available.

30.

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

31.

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.

Pelekanou V, Barlow WE, Nahleh ZA, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L.

Mol Cancer Ther. 2018 Jun;17(6):1324-1331. doi: 10.1158/1535-7163.MCT-17-1005. Epub 2018 Mar 27.

32.

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.

Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L.

Br J Cancer. 2018 Apr;118(8):1107-1114. doi: 10.1038/s41416-018-0030-0. Epub 2018 Mar 21.

33.

Exercise and weight loss interventions and miRNA expression in women with breast cancer.

Adams BD, Arem H, Hubal MJ, Cartmel B, Li F, Harrigan M, Sanft T, Cheng CJ, Pusztai L, Irwin ML.

Breast Cancer Res Treat. 2018 Jul;170(1):55-67. doi: 10.1007/s10549-018-4738-6. Epub 2018 Mar 6.

34.

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.

Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L.

Breast Cancer Res Treat. 2018 Jun;169(2):333-340. doi: 10.1007/s10549-017-4653-2. Epub 2018 Feb 2.

PMID:
29396664
35.

Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.

Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L.

JAMA Oncol. 2018 Apr 12;4(4):e175092. doi: 10.1001/jamaoncol.2017.5092. Epub 2018 Apr 12.

36.

Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A.

J Cancer Res Clin Oncol. 2018 Mar;144(3):601-606. doi: 10.1007/s00432-017-2574-4. Epub 2018 Jan 17.

PMID:
29344722
37.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E.

Breast Cancer Res Treat. 2018 Apr;168(3):631-638. doi: 10.1007/s10549-017-4628-3. Epub 2017 Dec 27.

38.

Functional germline variants as potential co-oncogenes.

Agarwal D, Nowak C, Zhang NR, Pusztai L, Hatzis C.

NPJ Breast Cancer. 2017 Nov 22;3:46. doi: 10.1038/s41523-017-0051-5. eCollection 2017. Review.

39.

Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer.

Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP.

JCO Clin Cancer Inform. 2017 Nov;1:1-10. doi: 10.1200/CCI.17.00015.

40.

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.

Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB.

J Oncol Pract. 2017 Dec;13(12):e1012-e1020. doi: 10.1200/JOP.2017.022731. Epub 2017 Oct 19.

PMID:
29048991
41.

Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?"

Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR.

Am J Surg. 2017 Dec;214(6):1089-1090. doi: 10.1016/j.amjsurg.2017.09.025. Epub 2017 Sep 30. No abstract available.

PMID:
28987415
42.

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT.

Ann Oncol. 2017 Oct 1;28(10):2420-2428. doi: 10.1093/annonc/mdx397.

43.

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Sep 25;19(1):109. doi: 10.1186/s13058-017-0898-2. No abstract available.

44.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

45.

Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?

Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR.

Am J Surg. 2017 Dec;214(6):1082-1088. doi: 10.1016/j.amjsurg.2017.07.036. Epub 2017 Sep 18.

PMID:
28939252
46.

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Aug 7;19(1):91. doi: 10.1186/s13058-017-0884-8. Erratum in: Breast Cancer Res. 2017 Sep 25;19(1):109.

47.

Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer.

Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR.

Ann Surg Oncol. 2017 Oct;24(10):3073-3081. doi: 10.1245/s10434-017-5936-x. Epub 2017 Aug 1.

PMID:
28766195
48.

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L.

JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.

49.

Is complete response the answer?

Pusztai L, Szekely B, Hatzis C.

Ann Oncol. 2017 Aug 1;28(8):1681-1683. doi: 10.1093/annonc/mdx215. No abstract available.

PMID:
28633466
50.

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Jun 6;8:15759. doi: 10.1038/ncomms15759.

Supplemental Content

Loading ...
Support Center